What does it mean to have a higher impaired fasting glucose risk score?

A higher score indicates your genetic variants — particularly in G6PC2, GCK, and MTNR1B — are associated with a tendency toward fasting blood glucose in the 100–125 mg/dL pre-diabetic range. It reflects a shifted beta-cell glucose set-point, not a certainty of developing diabetes. Lifestyle factors such as meal timing, sleep consistency, and physical activity can meaningfully offset this genetic tendency.

How does MTNR1B connect sleep to fasting glucose?

MTNR1B encodes the melatonin receptor expressed in pancreatic beta cells. Melatonin — the hormone that rises at night to signal sleep — binds this receptor and directly inhibits insulin secretion. People carrying the MTNR1B risk allele have heightened beta-cell sensitivity to melatonin, meaning more insulin suppression overnight. Eating late at night when melatonin is high leads to prolonged glucose elevation because insulin secretion is blunted at precisely the time a metabolic challenge arrives.

What is the GCK/G6PC2 rheostat?

Inside pancreatic beta cells, GCK phosphorylates glucose into glucose-6-phosphate — the signal that triggers insulin secretion. G6PC2 performs the opposing reaction, dephosphorylating glucose-6-phosphate back to glucose. This futile cycle means the ratio of GCK to G6PC2 activity determines how sensitive beta cells are to glucose. Higher G6PC2 activity damps the signal, raising the glucose concentration needed to trigger insulin.

Is impaired fasting glucose the same as pre-diabetes?

Impaired fasting glucose (100–125 mg/dL fasting) is one of two criteria used to define pre-diabetes. IFG as measured here reflects the fasting state specifically, where GCK and G6PC2 genetic effects are most directly expressed. A clinician can determine whether your fasting glucose readings, combined with other factors, meet criteria for a pre-diabetes designation.

What lifestyle changes are most effective for people with elevated genetic risk?

The three highest-leverage changes are: (1) shifting meals earlier in the day and avoiding food within two to three hours of bedtime; (2) exercising in the morning when melatonin is declining and insulin sensitivity is highest; and (3) replacing rapidly digested carbohydrates with lower-glycemic alternatives. Consistent sleep timing also stabilizes melatonin rhythm and limits overnight insulin suppression.

How is this trait different from the Blood Sugar Regulation trait?

The Blood Sugar Regulation trait covers broader glycemic genes including GCKR, ADCY5, ADRA2A, and CRY2. Impaired Fasting Glucose Risk is specifically anchored to fasting glucose biology and features G6PC2 — the GCK-opposing enzyme — and MTNR1B, the melatonin receptor, as its most distinctive contributors. The fasting window is where MTNR1B and G6PC2 effects are most prominent.

Impaired Fasting Glucose Risk and Your Genetics

Author: ExomeDNA Science Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

Impaired fasting glucose risk is shaped by genetic variants in G6PC2, GCK, MTNR1B, and SPC25 — genes that govern the beta-cell glucose-sensing rheostat, melatonin-driven insulin suppression, and the boundary between normal and pre-diabetic fasting glucose levels; a higher polygenic score on this trait indicates a tendency toward fasting glucose readings in the 100–125 mg/dL range. Below: how the GCK/G6PC2 balance sets your glucose threshold, why the sleep hormone melatonin matters for morning blood sugar, and evidence-based strategies for lowering your risk.

What is impaired fasting glucose?

Impaired fasting glucose (IFG) describes a fasting blood glucose level of 100–125 mg/dL — above the normal threshold of 99 mg/dL but below the 126 mg/dL level that defines type 2 diabetes. IFG sits in the zone clinicians often call pre-diabetes. At this stage, the body is still managing blood sugar, but the glucose-sensing machinery in pancreatic beta cells has shifted its set-point upward. Left unaddressed, IFG meaningfully raises the probability of progressing to type 2 diabetes over a five-to-ten year horizon. Genetics do not determine that outcome, but they do shape the baseline from which lifestyle choices operate. Understanding which genes are involved — and how they work — allows for more targeted and effective management strategies long before any diagnostic threshold is crossed.

The genetics behind impaired fasting glucose

Four genes anchor the genetic architecture of fasting glucose at this trait's GWAS locus: GCK, G6PC2, MTNR1B, and SPC25.

The central story is a molecular rheostat inside pancreatic beta cells. Glucokinase (GCK) is the enzyme that phosphorylates glucose into glucose-6-phosphate, a step that acts as the primary "glucose sensor" triggering insulin secretion. When blood glucose rises, GCK activity increases, glucose-6-phosphate accumulates, and the beta cell releases insulin. GCK essentially sets the minimum glucose concentration at which the cell decides to respond. Common GCK variants that reduce enzyme activity shift this threshold upward — the beta cell requires more glucose before it fires.

G6PC2 operates in direct opposition to GCK. This islet-specific enzyme, glucose-6-phosphatase catalytic subunit 2, dephosphorylates glucose-6-phosphate back to glucose — effectively reversing GCK's work. This creates a genuine futile cycle: GCK phosphorylates, G6PC2 dephosphorylates, and the ratio between their activities determines how sensitive the glucose-sensing mechanism is. Higher G6PC2 activity means more signal damping — a greater fraction of the glucose-6-phosphate is converted back to glucose before it can trigger insulin release. The net effect is an elevated fasting glucose set-point. G6PC2 variants that increase expression or enzymatic activity are among the strongest GWAS signals for fasting glucose in the human genome. The GCK/G6PC2 ratio, not either gene in isolation, is the actual determinant of beta-cell glucose threshold.

MTNR1B introduces a second, behaviorally modifiable layer to fasting glucose genetics. Melatonin receptor 1B is expressed in pancreatic beta cells — a fact that was counterintuitive when first discovered and remains one of the most compelling mechanistic links between circadian biology and metabolic health. Melatonin, the pineal gland hormone that rises at night to signal sleep onset, binds MTNR1B on beta cells and directly inhibits insulin secretion via Gi-coupled signaling: melatonin binding reduces cyclic AMP and suppresses insulin exocytosis. The MTNR1B rs10830963 risk allele is associated with higher receptor density or sensitivity, meaning more melatonin-mediated insulin suppression during nighttime hours. The practical consequence: eating a carbohydrate-containing meal late at night, when melatonin is at its peak, produces a longer-lasting glucose elevation in people carrying this variant. The beta cell is pharmacologically inhibited precisely when a metabolic challenge arrives. This gene links sleep timing, meal timing, and fasting glucose into a single coherent story with specific behavioral implications.

SPC25, a spindle pole body component involved in kinetochore assembly, appears at this GWAS locus but has less characterized functional biology in the context of glucose metabolism. Its inclusion reflects the statistical architecture of the locus rather than a well-understood mechanistic pathway.

What the research says

Research base: Robust.

The large-scale GWAS from Verma et al. (2024), drawing on the VA Million Veteran Program — one of the largest and most ancestrally diverse biobank studies in genomics — identified genetic architecture across 2,068 traits including impaired fasting glucose (PheCode 250.41) (PMID 39024449). The diversity and scale of this cohort strengthens confidence that the identified signals are not artifacts of a single ancestral population.

Key quantitative benchmarks from the fasting glucose GWAS literature place the G6PC2 locus among the top signals genome-wide, with effect sizes on the order of 0.06–0.10 mmol/L per allele for fasting glucose — small at the individual level, but highly reproducible and meaningful at the population level. MTNR1B rs10830963 shows effect sizes in a similar range, with meta-analyses across hundreds of thousands of individuals consistently replicating the association. The GCK locus contributes roughly 0.07 mmol/L per minor allele in large European cohorts.

Notable modifiers identified across the literature:

Meal timing — late-night eating amplifies the MTNR1B effect on fasting glucose
Sleep duration — short sleep raises fasting glucose independently of genetic background
Physical activity level — exercise increases GCK expression and improves insulin sensitivity
Dietary glycemic index — high-glycemic diets increase the challenge to the GCK/G6PC2 system
Circadian rhythm disruption — shift work and irregular sleep schedules worsen fasting glucose in MTNR1B risk carriers

The body of evidence is sufficiently robust that clinical guidelines from major diabetes organizations reference GCK and MTNR1B as functional anchors in the genetic epidemiology of pre-diabetes.

How impaired fasting glucose affects you

Fasting glucose in the IFG range (100–125 mg/dL) is typically asymptomatic. There are no symptoms that reliably distinguish someone with a fasting glucose of 108 mg/dL from someone at 92 mg/dL in daily life. This is precisely what makes the genetic context valuable — it surfaces a physiological tendency before any clinical signal appears. The GCK/G6PC2 set-point effect means the beta cell has simply been calibrated to tolerate higher ambient glucose before releasing insulin. The MTNR1B effect means the overnight window — when melatonin is high and insulin secretion is suppressed — is the period of greatest metabolic vulnerability. Morning fasting glucose levels, drawn after an overnight fast that coincides with peak melatonin, are where these genetic tendencies are most directly expressed. Over years, chronic mild glucose elevation increases exposure of vessels and organs to glycation, the non-enzymatic attachment of glucose to proteins, even at sub-diabetic levels. IFG is a modifiable state, not a fixed outcome, and the genetics that define the risk also point toward the most effective places to intervene.

Working with your impaired fasting glucose result

A higher result on this trait calls for targeted adjustments in meal timing, sleep hygiene, and physical activity — the three domains most directly connected to GCK, G6PC2, and MTNR1B biology.

Move meals earlier in the day. When melatonin is low — morning through mid-afternoon — beta-cell insulin secretion is uninhibited. Consuming most daily calories and carbohydrates earlier shifts metabolic processing to the window of highest insulin competence. Avoiding eating within two to three hours of bedtime is especially important for people carrying the MTNR1B risk allele.
Maintain a consistent sleep schedule. Irregular sleep timing disrupts melatonin rhythm and extends the duration of nighttime insulin suppression into morning hours. Going to bed and waking at consistent times stabilizes circadian melatonin peaks, which helps define a clear boundary between the insulin-suppressed overnight window and the active metabolic day.
Prioritize morning physical activity. Exercise is one of the most potent upregulators of GCK expression and improves peripheral insulin sensitivity. Morning exercise occurs when melatonin is declining and insulin sensitivity is highest, making it the most metabolically effective timing for people with elevated fasting glucose risk.
Reduce simple and rapidly digested carbohydrates. Lower-glycemic meals produce a smaller and slower glucose challenge to the GCK/G6PC2 sensing system. This is not about eliminating carbohydrates but about selecting sources — whole grains, legumes, vegetables — that produce a gradual glucose rise the beta cell can manage within its set-point range.
Build consistent daily movement into non-exercise hours. Postprandial walking — even ten to fifteen minutes after meals — measurably blunts glucose excursions and reduces the chronic glucose load that drives IFG progression.
Schedule annual fasting glucose and HbA1c monitoring. IFG identified early is highly amenable to reversal. People carrying GCK and MTNR1B risk variants benefit from knowing their trajectory year over year, as modest lifestyle changes can hold fasting glucose below diagnostic thresholds for decades when begun early. A clinician can interpret these results in the context of your full health picture and recommend appropriate follow-up.

Impaired fasting glucose sits at the intersection of several related metabolic traits covered elsewhere in ExomeDNA results. Blood Sugar Regulation (TRAIT_067863) examines the broader glycemic architecture including GCKR, ADCY5, ADRA2A, and CRY2, providing a complementary view of post-meal glucose handling alongside fasting levels. Type 2 Diabetes Risk captures the downstream outcome that IFG represents a precursor to, integrating polygenic risk across dozens of loci. Caffeine Metabolism (CYP1A2) is relevant because caffeine's effects on insulin sensitivity interact with circadian timing in ways that affect fasting glucose. Sleep Duration and Chronotype traits address the circadian biology through which MTNR1B exerts its influence on metabolic health. Obesity-Related Traits share upstream genetic architecture with metabolic glucose risk through pathways involving adipokine signaling and hepatic glucose output. GCK, when bearing rare pathogenic variants rather than common polygenic risk alleles, is also the defining gene for MODY2 (maturity-onset diabetes of the young type 2), a monogenic form of mildly elevated fasting glucose — a distinct condition covered under ExomeDNA's Monogenic Risk section.

Frequently asked questions

See below for answers to the questions most commonly raised about this trait.

References: Verma A et al. Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science. 2024. PMID 39024449.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.

Browse all traits →